Fox Chase Cancer Center, part of the Temple University Health System in Philadelphia, has received a grant for $673,000 from the U.S. Department of Defense to develop an improved method for screening for lung cancer.
Martin J. Edelman, MD, chair of the department of Hematology/Oncology at Fox Chance Cancer Center, and colleagues will work on research focused on using cancer associated macrophage-like (CAML) cells to determine if a small or indeterminate lung nodule is malignant or benign.
“Low-dose CT scans have the potential to dramatically lower lung cancer death rates, but there are too many indeterminate cases and false positives,” Edelman said in a prepared statement. “We are working on a simple, minimally invasive test for CAMLs, which will serve as second-level screening for patients whose lung scans are inconclusive.”
The team’s study is set to take place at both Fox Chase Cancer Center and the Philadelphia VA.